Skip to main content
. 2021 Mar 31;12:613449. doi: 10.3389/fphar.2021.613449

FIGURE 2.

FIGURE 2

PMN-endothelial cell interactions. HUVEC and PMN were incubated (4 h) with ABC (20 µmol/L), ATP (0.05–10 µmol/L), CBV-TP (10–50 µmol/L), Bz-ATP (100 µmol/L) or vehicle (veh). In some cases, both cell types (HUVEC and PMN) were pretreated with suramin (Sur, non-selective P2R antagonist, 100 μmol/L, 60 min) or with A804598 (A80, P2X7R antagonist, 1 μmol/L, 30 min) prior to ABC (20 µmol/L), ATP (1 µmol/L) or CBV-TP (20 µmol/L). PMN rolling velocity (A, B), PMN rolling flux (C, D) and PMN adhesion (E, F) were quantified. Results are mean ± SEM, Veh: n ≥ 14, ABC: n ≥ 7, ATP 0.05: n ≥ 4, ATP 0.1: n ≥ 13, ATP 1: n ≥ 6, ATP 10: n ≥ 6, CBV-TP 10: n ≥ 6, CBV-TP 20: n ≥ 5, CBV-TP 30: n ≥ 5, CBV-TP 50: n ≥ 6, Bz-ATP 100: n ≥ 6, ABC 20 + Sur: n ≥ 4, ABC 20 + A80: n ≥ 4, ATP 1 + Sur: n ≥ 6, ATP 1 + A80: n ≥ 5, CBV-TP 20 + Sur: n ≥ 5, CBV-TP 20 + A80: n ≥ 5. *p < 0.05 or **p < 0.01 vs. corresponding value in vehicle-treated group. +p < 0.05 or ++p < 0.01 vs. corresponding value in ABC, ATP or CBV-TP-treated group (ANOVA followed by Newman-Keuls test).